+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Global Biosimilars Monoclonal Antibodies Market Set To Grow To $5.9bn By 2023

02 August 2018
Pharma

Visiongain’ has launched a new pharma report Biosimilar Monoclonal Antibodies Market Report : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars. The result is an R&D pipeline holding at least 86 biosimilar mAb candidates. Emerging markets with less stringent regulatory processes, such as India and Russia, dominated shares of the market in 2017. However, in addition to China, the more developed markets of the US and the EU5 will increase their market shares throughout the forecast period as patents expire on the originator products.

The lead analyst of the report commented “The biosimilar mAbs market will face challenges posed by competition from biobetters and a lack of confidence of some clinicians in biosimilar interchangeability. However, these challenges will be overcome owing to the high demand worldwide for affordable biological drugs, especially therapeutic monoclonal antibodies. Visiongain expects governmental policy to increase preferences for the use of biosimilars mAbs over branded ones as healthcare budgets become increasingly strained. Biosimilar mAbs will therefore have an important, rising role to play in healthcare systems from 2016 to 2028.”

Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science, Genor Biopharma, Harvest Moon, Hospira, Mabion, Pfizer, Samsung Bioepsis

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read